Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Modulation of the renin-angiotensin-aldosterone system is a foundation of therapy for
cardiovascular and kidney diseases. Excess aldosterone plays an important role in …
cardiovascular and kidney diseases. Excess aldosterone plays an important role in …
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
KR Tuttle, SJ Hauske, ME Canziani, ML Caramori… - The Lancet, 2024 - thelancet.com
Background Excess aldosterone accelerates chronic kidney disease progression. This
phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy …
phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy …
[HTML][HTML] Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
A Mazzieri, F Porcellati, F Timio, G Reboldi - International Journal of …, 2024 - mdpi.com
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …
Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study
BACKGROUND: Primary aldosteronism, characterized by overt renin-independent
aldosterone production, is a common but underrecognized form of hypertension and …
aldosterone production, is a common but underrecognized form of hypertension and …
The spectrum of dysregulated aldosterone production: An international human physiology study
WW Parksook, JM Brown, K Omata… - The Journal of …, 2024 - academic.oup.com
Context Primary aldosteronism is a form of low-renin hypertension characterized by
dysregulated aldosterone production. Objective To investigate the contributions of renin …
dysregulated aldosterone production. Objective To investigate the contributions of renin …
[HTML][HTML] The Global burden of resistant hypertension and potential treatment options
G Buso, C Agabiti-Rosei, M Lemoli… - European Cardiology …, 2024 - ncbi.nlm.nih.gov
Resistant hypertension (RH) is defined as systolic blood pressure (SBP) or diastolic blood
pressure (DBP) that remains. 140 mmHg or. 90 mmHg, respectively, despite an appropriate …
pressure (DBP) that remains. 140 mmHg or. 90 mmHg, respectively, despite an appropriate …
Methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease
KR Tuttle - 2023 - karger.com
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone
Synthase Inhibition in Chronic K Page 1 AJN American Journal of Nephrology Methods Article …
Synthase Inhibition in Chronic K Page 1 AJN American Journal of Nephrology Methods Article …
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind …
SR Bornstein, D de Zeeuw… - Diabetes, Obesity …, 2024 - Wiley Online Library
Abstract Aim This Phase I study evaluated the safety and early efficacy of an aldosterone
synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney …
synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney …
A new dawn for aldosterone as a therapeutic target in hypertension
B Williams - JAMA, 2023 - jamanetwork.com
In 1953, aldosterone, then termed electrocortin, was first isolated and characterized by
James and Sylvia Tait in London. 1 A year later, Jerome Conn described the first case of …
James and Sylvia Tait in London. 1 A year later, Jerome Conn described the first case of …
Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors
JM Feldman, WH Frishman, WS Aronow - Cardiology in review, 2024 - journals.lww.com
The target-hypertension (Target-HTN) trial investigated the efficacy and safety of
lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial …
lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial …